Plus Therapeutics FY2025 net loss $22.4M; cash $13.1M, outlines 2026 milestones for REYOBIQ and CNSide

PLUS THERAPEUTICS, INC.

Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.
Cash and investments $13.1M at Dec 31, 2025 (up from $3.6M); raised $15M gross in upsized public offering.
CNSide lab licensed in 49 states; coverage agreements with Humana and UnitedHealthcare reach ~67M lives.
2026 milestones: REYOBIQ Phase 2 LM data Q3 2026, GBM data Q4; CNSide target >1,250 annual test orders, breakeven by 2027.
Secured AMA Category III CPT code for convection-enhanced delivery with REYOBIQ, unlocking market access.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.